

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Most Kwai Chung Limited

毛記葵涌有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1716)

**COMPLETION OF DISCLOSEABLE TRANSACTIONS
ACQUISITION OF TARGET COMPANIES**

Reference is made to the announcement of Most Kwai Chung Limited (the “**Company**”) dated 31 August 2026 in relation to the discloseable transactions regarding the acquisitions of the Wannianfeng Sale Interest and the Zhousha Sale Interest (the “**Announcement**”). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that as the Vendor has completed the registrations with relevant local branch registration office(s) of SAMR of the respective transfers of the Wannianfeng Sale Interest and the Zhousha Sale Interest from the Vendor to the Company, as of 26 October 2026 completion of the Wannianfeng Acquisition and the Zhousha Acquisition have taken place in accordance with the terms and conditions of the Wannianfeng SPA and the Zhousha SPA respectively.

Upon completion of the Wannianfeng Acquisition and the Zhousha Acquisition, the Company has become the legal and beneficial owner of the entire equity interest in each of Wannianfeng and Zhousha. Since Wannianfeng and Zhousha have become wholly owned subsidiaries of the Company, the respective financial results of Wannianfeng and Zhousha will be consolidated into the consolidated financial statements of the Group.

By order of the Board
MOST KWAI CHUNG LIMITED
毛記葵涌有限公司
Ma Liyang
Chairman and Executive Director

Hong Kong, 26 October 2026

As at the date of this announcement, the Board comprises Dr. Ma Liyang (Chairman) and Ms. Cheng Taohong, being the executive Directors; and Dr. Chen Yang, Dr. Yuan Yuan and Ms. Yuan Fan, being the independent non-executive Directors.